NCT06143514 — "A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk" trial site landscape

Public-registry site landscape for NCT06143514, “A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk”, a Relapsing Multiple Sclerosis study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT06143514 (registry record)
Study title	A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Official title	A Post-marketing Study Evaluating the Presence and Concentration of BRIUMVI™ in Breast Milk (PROVIDE)
Sponsor	TG Therapeutics, Inc.
Condition(s)	Relapsing Multiple Sclerosis
Phase	—
Listed sites	5
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT06143514.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT06143514 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Relapsing Multiple Sclerosis trials

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

More from TG Therapeutics, Inc.

← Eichor home · All tracked trials · Relapsing Multiple Sclerosis studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →